Third Age Health Services

No quantified FY23 guidance or medium-term financial targets were provided in the supplied material. The half-year shape is mixed: HY22 represented 48.1% of full-year revenue but 57.3% of full-year NPAT, implying the second half was weaker on profitability than the first despite full-period contribution from the October 2021 GP acquisition. That pattern is not supportive of an accelerating earnings trajectory into FY23 on the information disclosed, though acquisition integration timing could explain part of it.

• What drove the effective tax rate from 32.9% to 24.9%, and is the lower rate sustainable?
• Why did operating cash flow fall NZD 0.5m when PBT was flat — beyond the modest receivables stretch, what other working-capital or timing items contributed?
• What was the FY22 segment revenue and result split between Aged medical care and General Practice, given FY21 was 86.6%/13.4%?
• What are the acquisition economics: purchase price, goodwill, and contribution margin of the community GPs acquired?
• Was the HY22-to-2H22 profit step-down a function of integration costs, seasonality, or underlying margin pressure?

This briefing cannot assess valuation, management guidance for FY23, or leverage capacity, because NTA per share, forward targets, and any debt-facility detail were not disclosed in the supplied extraction.